The FDA's application record carries an action on ANDA 208934, tadalafil, sponsored by Sun Pharmaceutical. An abbreviated new drug application is the generic pathway, so this concerns a copy of an already licensed product rather than a new medicine, a new indication or a safety communication. The record does not say what the supplement covers.
There is nothing here to change prescribing. Tadalafil's indications, doses and interactions are unchanged, and the nitrate contraindication remains the thing that matters most in a urology clinic.
The one point worth noting is supply. Generic entry and generic supplements are what determine price and availability, and tadalafil is already inexpensive and widely available in India, where Sun Pharmaceutical is a domestic manufacturer. A US generic action does not alter Indian availability, and the record says nothing about CDSCO status. For a patient asking whether a cheaper version is coming, the answer is that this is a routine regulatory filing rather than news.
- No change to tadalafil indications, dosing or contraindications follows from this
- The absolute contraindication with nitrates is unchanged and is the safety point that matters
- Ask about over-the-counter and online tadalafil sources - unlabelled use is common
- A US generic filing does not affect Indian availability or CDSCO status
- Check the current label directly if a patient asks what the supplement covers
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for urology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free